Shionogi & Co., Ltd. (SGIOF) Stock Price & Analysis
Shionogi & Co., Ltd. (SGIOF) — price $16.44 (+0.31%), as of the Oct 2, 2026 trading session; market cap $14.0B.
Educational signal · not a buy or sell recommendation · How to read this
Shionogi & Co., Ltd. · SGIOF
Shionogi & Co., Ltd. is a leading pharmaceutical company based in Japan, specializing in the development of innovative drugs and medical devices. With a strong focus on addressing unmet medical needs, the company has established a diverse portfolio of products targeting various therapeutic areas.
Price as of Oct 2, 2026
Key Statistics
MoonshotScore is not published for this security.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $16.44 | |
| Change on the day | +0.31% | |
| 52-week range | $14.25 – $26.00 | |
| Market capitalisation | $14.0B | |
| Price / earnings (trailing) | 8.93 | |
| Shares traded on the day | 10 |
Price & events
Other perspectives
Council score for Shionogi & Co. (SGIOF): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Legends Council
5 lenses, 5 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Oct 5, 2026
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 11, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 11, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.
Readings on this page are from Oct 5, 2026, except a card that shows its own read date.
Watch the SGIOF film — every key number, told as a short cinematic story
~2 min · open the film
What is Shionogi & Co. (SGIOF), and what does it report?
Short answer · as of
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Shionogi & Co., Ltd. (SGIOF) is the company analyzed here. It employs 6,223 people and is led by Isao Teshirogi. In Q1 FY2026 it reported revenue of $1.03B and net income of $614M. The market values it at $14.0B.
What do the latest results show for Shionogi & Co. (SGIOF)?
Short answer · as of
The most recent reported quarter, Q1 FY2026, carried revenue of $1.03B. Against analyst estimates the company has EPS beat 7 of 8 reports.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q1 FY2026 | $1.03B | $614M | $0.72 (diluted) |
| Q4 FY2025 | $885M | $299M | $0.35 (diluted) |
| Q3 FY2025 | $936M | $473M | $0.56 (diluted) |
| Q2 FY2025 | $727M | $284M | $0.33 (diluted) |
What are the financial strengths and risks for Shionogi & Co. (SGIOF)?
Short answer
The distress and quality screens read Altman Z 2.87 · Piotroski F 3. Trailing ratios: ROE 16.5% · ROA 9.9% · current ratio 1.14 · earnings yield 10.9% · free-cash-flow yield 8.3%.
What should you watch next at Shionogi & Co. (SGIOF)?
Short answer · as of
Analyst estimates on file carry FY2027 revenue $707.54B · EPS 269.39 · 12 analysts.
What the records here don't tell us
- The next earnings date is not yet scheduled in the calendar we read.
- No insider Form 4 transaction falls inside the window this page reads.
Checked against the records this page reads, on the dates shown above.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Revenue estimate
- $707.54B
- EPS estimate
- $269.39
Measured against a quoted price of $16.44 (as of Oct 2, 2026).
Common Questions About SGIOF
These answers are editorial: 1 of these 8 answers is drawn from the SGIOF research dossier (written Mar 17, 2026 by gpt-4o-mini); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.
Is SGIOF a good stock to buy?
Stock Expert AI does not rate SGIOF buy, sell or hold. Shionogi & Co., Ltd. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the SGIOF stock price today?
The last price recorded on this page for Shionogi & Co., Ltd. (SGIOF) is $16.44, as of the Oct 2, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What are the main risks for SGIOF?
Shionogi & Co., Ltd. faces several risks, including potential regulatory hurdles that could delay drug approvals and market entry. Ongoing competitive pressures from other pharmaceutical companies may impact market share, while the volatility associated with the OTC market could affect stock performance.
What are the key factors to evaluate for SGIOF?
Evaluate SGIOF on fundamentals, analyst consensus, and risk factors. P/E: 8.93x. With a growing patient population seeking effective pain relief, successful commercialization of this drug could lead to substantial revenue growth. Not financial advice.
How frequently does SGIOF data refresh on this page?
SGIOF's price is the last quote we recorded, from the Oct 2, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven SGIOF's recent stock price performance?
Shionogi & Co., Ltd. (SGIOF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Robust pipeline of innovative drugs targeting high unmet medical needs. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider SGIOF overvalued or undervalued right now?
Shionogi & Co., Ltd. (SGIOF) trades at 8.93x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research SGIOF before investing?
Before investing in Shionogi & Co., Ltd. (SGIOF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Machine-generated analysis by Stock Expert AI — model gpt-4o-mini, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (18 figures)
The 18 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
FMP — 9 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.last | Latest provided price | $16.44 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-05T08:54:40.088Z. | |
px.change | Change on the day | +0.31% | FMP | Financial Modeling Prep (FMP) · quote | |
px.mcap | Market capitalisation | $14.0B | FMP | Financial Modeling Prep (FMP) · quote — Date unknown Market cap record date: 2026-10-02. FMP quote timestamp: 2026-10-02T20:00:00.000Z. Captured from FMP at 2026-10-05T08:54:38.127Z. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares. | |
px.change_abs | Change on the day, in dollars | +$0.05 | FMP | Financial Modeling Prep (FMP) · quote | |
px.pe | Price / earnings (trailing) | 8.93 | FMP | Financial Modeling Prep (FMP) · quote | |
px.volume | Shares traded on the day | 10 | FMP | Financial Modeling Prep (FMP) · quote | |
fin.q_revenue | Revenue, Q1 FY2026 | $1.03B | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
fin.q_income | Net income, Q1 FY2026 | $614M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
fin.q_table | Quarterly income statement | 4 quarters through Q1 FY2026 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed |
UNRECORDED — 9 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.range52 | 52-week range | $14.25 – $26.00 | UNRECORDED | Stored company-profile observation — Captured 2026-10-01 | |
id.employees | Employees | 6,223 | UNRECORDED | Stored company-profile observation — Captured 2026-10-01 | |
id.ceo | Chief executive | Isao Teshirogi | UNRECORDED | Stored company-profile observation — Captured 2026-10-01 | |
earn.history | Reported versus estimated, recent quarters | EPS beat 7 of 8 | UNRECORDED | Stored earnings-history observation — Captured 2026-10-01 · Expired observation | |
fin.scores | Distress and quality screens | Altman Z 2.87 · Piotroski F 3 | UNRECORDED | Stored financial-scores observation — Captured 2026-10-05 | |
fin.ratios | Return and yield ratios (trailing twelve months) | ROE 16.5% · ROA 9.9% · current ratio 1.14 · earnings yield 10.9% · free-cash-flow yield 8.3% | — | UNRECORDED | Stored key metrics — Date unknown |
earn.estimates | Analyst estimates, next fiscal year | FY2027 revenue $707.54B · EPS 269.39 · 12 analysts | UNRECORDED | Stored analyst estimates — Captured 2026-10-04 · Expired observation | |
earn.est_revenue | Revenue estimate, FY2027 | $707.54B | UNRECORDED | Stored analyst estimates — Captured 2026-10-04 · Expired observation | |
earn.est_eps | EPS estimate, FY2027 | $269.39 | UNRECORDED | Stored analyst estimates — Captured 2026-10-04 · Expired observation |
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Data provided for informational purposes only.